Bioenvision to Present at 2007 UBS Global Generic and Specialty Pharmaceuticals Conference
May 03 2007 - 7:02AM
Business Wire
Bioenvision, Inc. (Nasdaq: BIVN) today announced Jim Scibetta,
chief financial officer of the Company, will be giving a
presentation at the 2007 UBS Global Generic and Specialty
Pharmaceuticals Conference on Wednesday, May 9, 2007 at 1:00PM
Eastern Time. The conference is being held at the Grand Hyatt New
York at Grand Central Station in New York City. The audio portion
of the presentation will be webcast live and available on the
webcast section of the Company�s website, www.bioenvision.com. The
webcast will be archived and the link will remain active through
June 8, 2007. About Bioenvision Bioenvision's primary focus is the
acquisition, development and marketing of compounds and
technologies for the treatment of cancer. Bioenvision has a broad
pipeline of products for the treatment of cancer, including:
Evoltra�, Modrenal� (for which Bioenvision has obtained regulatory
approval for marketing in the United Kingdom for the treatment of
post-menopausal breast cancer following relapse to initial hormone
therapy), and other products. Bioenvision is also developing Suvus�
which is currently in clinical development for refractory chronic
hepatitis C infection. For more information on Bioenvision please
visit our website at www.bioenvision.com. Certain statements
contained herein are "forward-looking" statements (as such term is
defined in the Private Securities Litigation Reform Act of 1995).
Because these statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Specifically, factors that could
cause actual results to differ materially from those expressed or
implied by such forward-looking statements include, but are not
limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the
potential failure of Bioenvision's compounds under development to
prove safe and effective for treatment of disease; uncertainties
inherent in the early stage of Bioenvision's compounds under
development; failure to successfully implement or complete clinical
trials; failure to receive marketing clearance from regulatory
agencies for our compounds under development; acquisitions,
divestitures, mergers, licenses or strategic initiatives that
change Bioenvision's business, structure or projections; the
development of competing products; uncertainties related to
Bioenvision's dependence on third parties and partners; and those
risks described in Bioenvision's filings with the SEC. Bioenvision
disclaims any obligation to update these forward-looking
statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From May 2024 to Jun 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2023 to Jun 2024